C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy
Background. Our aim was to define the conditions that affect therapeutic success when dipeptidyl peptidase-4 (DPP-4) inhibitor is added to metformin monotherapy. Materials and Methods. We reviewed the medical records of 56 patients who had received DPP-4 inhibitor as an add-on to metformin monothera...
Saved in:
Main Authors: | Sevin Demir, Sule Temizkan, Mehmet Sargin |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2016-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2016/4509603 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus
by: Pegah Yousefzadeh, et al.
Published: (2013-01-01) -
Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice
by: Seung Hee Choi, et al.
Published: (2017-01-01) -
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
by: Jixin Zhong, et al.
Published: (2015-01-01) -
Identification and dipeptidyl peptidase IV (DPP-IV) inhibitory activity verification of peptides from mouse lymphocytes
by: Juan Wang, et al.
Published: (2022-11-01) -
Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice
by: Wenbin Zheng, et al.
Published: (2018-01-01)